Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms, and mechanisms

Andrew P. AllenAPC Microbiome Institute, University College Cork, Cork, Ireland; ;Department of Psychiatry & Neurobehavioural Science, University College Cork, Cork, Ireland; Correspondence[email protected]

Gerard ClarkeAPC Microbiome Institute, University College Cork, Cork, Ireland; ;Department of Psychiatry & Neurobehavioural Science, University College Cork, Cork, Ireland;

John F. CryanAPC Microbiome Institute, University College Cork, Cork, Ireland; ;Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland;

Eamonn M. M. QuigleyDivision of Gastroenterology and Hepatology, Lynda K and David M Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA

Timothy G. DinanAPC Microbiome Institute, University College Cork, Cork, Ireland; ;Department of Psychiatry & Neurobehavioural Science, University College Cork, Cork, Ireland;

Click to increase image sizeClick to decrease image size

Transparency

Declaration of funding

This commentary received no funding.

Declaration of financial/other relationships

The authors have no financial/other relationships to declare.

Acknowledgments

The APC Microbiome Institute is a research centre funded by Science Foundation Ireland, through the Irish Government's National Development Plan. The authors and their work are supported by Science Foundation Ireland (grant number SFI/12/RC/2273) and through EU GRANT 613979 (MYNEWGUT FP7-KBBE-2013-7). The first author is supported by the Health Research Board through Health Research Awards (grant number HRA-POR-2-14-647; GC) and by the Health Service Executive through the Healthy Ageing Award (HaPAI/2015/GC). These funding bodies did not play any role in the writing of this editorial.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms, and mechanisms

Declaration of funding

Declaration of financial/other relationships

Information for

Open access

Opportunities

Help and information

Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms, and mechanisms

Transparency

Declaration of funding

Declaration of financial/other relationships

Acknowledgments

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature